Intrinsic value of Agenus - AGEN

Previous Close

$2.19

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$2.19

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of AGEN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  69
  106
  159
  230
  324
  446
  599
  786
  1,012
  1,278
  1,587
  1,940
  2,338
  2,782
  3,271
  3,805
  4,384
  5,005
  5,668
  6,373
  7,118
  7,902
  8,725
  9,586
  10,486
  11,425
  12,402
  13,418
  14,476
  15,574
Variable operating expenses, $m
  76
  115
  171
  246
  345
  473
  634
  831
  1,069
  1,349
  1,670
  2,042
  2,462
  2,929
  3,444
  4,006
  4,614
  5,268
  5,967
  6,708
  7,492
  8,318
  9,184
  10,091
  11,038
  12,026
  13,055
  14,125
  15,238
  16,394
Fixed operating expenses, $m
  106
  109
  111
  113
  116
  119
  121
  124
  127
  129
  132
  135
  138
  141
  144
  147
  151
  154
  157
  161
  164
  168
  172
  175
  179
  183
  187
  191
  195
  200
Total operating expenses, $m
  182
  224
  282
  359
  461
  592
  755
  955
  1,196
  1,478
  1,802
  2,177
  2,600
  3,070
  3,588
  4,153
  4,765
  5,422
  6,124
  6,869
  7,656
  8,486
  9,356
  10,266
  11,217
  12,209
  13,242
  14,316
  15,433
  16,594
Operating income, $m
  -114
  -118
  -123
  -129
  -137
  -146
  -156
  -169
  -184
  -200
  -216
  -237
  -261
  -288
  -316
  -348
  -381
  -417
  -456
  -496
  -539
  -584
  -631
  -680
  -731
  -785
  -840
  -898
  -958
  -1,020
EBITDA, $m
  -103
  -104
  -104
  -103
  -101
  -98
  -94
  -88
  -81
  -72
  -61
  -48
  -33
  -16
  3
  24
  47
  72
  98
  127
  157
  189
  222
  257
  294
  332
  372
  414
  458
  503
Interest expense (income), $m
  1
  21
  17
  28
  45
  66
  95
  132
  179
  236
  305
  387
  481
  589
  711
  846
  996
  1,159
  1,336
  1,525
  1,728
  1,943
  2,171
  2,411
  2,662
  2,925
  3,200
  3,487
  3,786
  4,096
  4,419
Earnings before tax, $m
  -135
  -135
  -152
  -174
  -203
  -241
  -289
  -348
  -420
  -506
  -602
  -718
  -850
  -998
  -1,163
  -1,343
  -1,540
  -1,753
  -1,981
  -2,224
  -2,482
  -2,755
  -3,041
  -3,342
  -3,657
  -3,985
  -4,327
  -4,683
  -5,054
  -5,439
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -135
  -135
  -152
  -174
  -203
  -241
  -289
  -348
  -420
  -506
  -602
  -718
  -850
  -998
  -1,163
  -1,343
  -1,540
  -1,753
  -1,981
  -2,224
  -2,482
  -2,755
  -3,041
  -3,342
  -3,657
  -3,985
  -4,327
  -4,683
  -5,054
  -5,439

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  182
  281
  420
  610
  861
  1,183
  1,588
  2,086
  2,684
  3,390
  4,209
  5,146
  6,203
  7,380
  8,677
  10,094
  11,627
  13,275
  15,035
  16,904
  18,879
  20,959
  23,143
  25,428
  27,815
  30,304
  32,896
  35,593
  38,397
  41,311
Adjusted assets (=assets-cash), $m
  182
  281
  420
  610
  861
  1,183
  1,588
  2,086
  2,684
  3,390
  4,209
  5,146
  6,203
  7,380
  8,677
  10,094
  11,627
  13,275
  15,035
  16,904
  18,879
  20,959
  23,143
  25,428
  27,815
  30,304
  32,896
  35,593
  38,397
  41,311
Revenue / Adjusted assets
  0.379
  0.377
  0.379
  0.377
  0.376
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
  0.377
Average production assets, $m
  72
  111
  166
  241
  339
  467
  626
  822
  1,058
  1,337
  1,660
  2,029
  2,446
  2,910
  3,422
  3,980
  4,585
  5,235
  5,929
  6,666
  7,445
  8,265
  9,126
  10,027
  10,969
  11,950
  12,972
  14,036
  15,142
  16,291
Working capital, $m
  -36
  -55
  -83
  -120
  -169
  -233
  -313
  -410
  -528
  -667
  -828
  -1,013
  -1,221
  -1,452
  -1,708
  -1,986
  -2,288
  -2,613
  -2,959
  -3,327
  -3,715
  -4,125
  -4,554
  -5,004
  -5,474
  -5,964
  -6,474
  -7,004
  -7,556
  -8,130
Total debt, $m
  133
  222
  348
  518
  744
  1,034
  1,399
  1,846
  2,385
  3,020
  3,758
  4,601
  5,552
  6,611
  7,779
  9,054
  10,434
  11,917
  13,501
  15,183
  16,961
  18,833
  20,798
  22,855
  25,003
  27,243
  29,576
  32,003
  34,527
  37,150
Total liabilities, $m
  164
  253
  378
  549
  775
  1,065
  1,429
  1,877
  2,415
  3,051
  3,788
  4,631
  5,582
  6,642
  7,810
  9,085
  10,465
  11,948
  13,532
  15,213
  16,991
  18,864
  20,828
  22,885
  25,033
  27,273
  29,606
  32,034
  34,557
  37,180
Total equity, $m
  18
  28
  42
  61
  86
  118
  159
  209
  268
  339
  421
  515
  620
  738
  868
  1,009
  1,163
  1,328
  1,504
  1,690
  1,888
  2,096
  2,314
  2,543
  2,781
  3,030
  3,290
  3,559
  3,840
  4,131
Total liabilities and equity, $m
  182
  281
  420
  610
  861
  1,183
  1,588
  2,086
  2,683
  3,390
  4,209
  5,146
  6,202
  7,380
  8,678
  10,094
  11,628
  13,276
  15,036
  16,903
  18,879
  20,960
  23,142
  25,428
  27,814
  30,303
  32,896
  35,593
  38,397
  41,311
Debt-to-equity ratio
  7.320
  7.910
  8.270
  8.500
  8.650
  8.740
  8.810
  8.850
  8.890
  8.910
  8.930
  8.940
  8.950
  8.960
  8.960
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -135
  -135
  -152
  -174
  -203
  -241
  -289
  -348
  -420
  -506
  -602
  -718
  -850
  -998
  -1,163
  -1,343
  -1,540
  -1,753
  -1,981
  -2,224
  -2,482
  -2,755
  -3,041
  -3,342
  -3,657
  -3,985
  -4,327
  -4,683
  -5,054
  -5,439
Depreciation, amort., depletion, $m
  10
  14
  19
  26
  35
  47
  62
  81
  103
  129
  155
  190
  229
  272
  320
  372
  429
  489
  554
  623
  696
  772
  853
  937
  1,025
  1,117
  1,212
  1,312
  1,415
  1,523
Funds from operations, $m
  -124
  -121
  -132
  -148
  -168
  -194
  -227
  -267
  -317
  -377
  -447
  -528
  -621
  -726
  -843
  -971
  -1,112
  -1,264
  -1,427
  -1,601
  -1,787
  -1,982
  -2,189
  -2,405
  -2,632
  -2,868
  -3,115
  -3,372
  -3,639
  -3,917
Change in working capital, $m
  -13
  -20
  -27
  -37
  -49
  -63
  -80
  -98
  -118
  -139
  -161
  -184
  -208
  -232
  -255
  -279
  -302
  -324
  -346
  -368
  -389
  -409
  -430
  -450
  -470
  -490
  -510
  -531
  -552
  -574
Cash from operations, $m
  -111
  -101
  -105
  -110
  -118
  -130
  -147
  -170
  -200
  -238
  -286
  -344
  -413
  -494
  -587
  -693
  -810
  -939
  -1,081
  -1,234
  -1,398
  -1,573
  -1,759
  -1,955
  -2,162
  -2,378
  -2,605
  -2,841
  -3,087
  -3,343
Maintenance CAPEX, $m
  -4
  -7
  -10
  -15
  -22
  -32
  -44
  -59
  -77
  -99
  -125
  -155
  -190
  -229
  -272
  -320
  -372
  -429
  -489
  -554
  -623
  -696
  -772
  -853
  -937
  -1,025
  -1,117
  -1,212
  -1,312
  -1,415
New CAPEX, $m
  -27
  -39
  -55
  -75
  -99
  -127
  -160
  -196
  -236
  -278
  -323
  -369
  -417
  -464
  -512
  -559
  -605
  -650
  -694
  -737
  -779
  -820
  -861
  -901
  -941
  -982
  -1,022
  -1,063
  -1,106
  -1,149
Cash from investing activities, $m
  -31
  -46
  -65
  -90
  -121
  -159
  -204
  -255
  -313
  -377
  -448
  -524
  -607
  -693
  -784
  -879
  -977
  -1,079
  -1,183
  -1,291
  -1,402
  -1,516
  -1,633
  -1,754
  -1,878
  -2,007
  -2,139
  -2,275
  -2,418
  -2,564
Free cash flow, $m
  -142
  -147
  -170
  -201
  -240
  -289
  -350
  -424
  -512
  -615
  -734
  -869
  -1,020
  -1,187
  -1,371
  -1,571
  -1,787
  -2,018
  -2,264
  -2,525
  -2,800
  -3,089
  -3,392
  -3,709
  -4,040
  -4,385
  -4,744
  -5,117
  -5,505
  -5,907
Issuance/(repayment) of debt, $m
  -30
  89
  125
  171
  226
  290
  365
  448
  538
  635
  738
  843
  951
  1,060
  1,168
  1,275
  1,380
  1,483
  1,584
  1,682
  1,778
  1,872
  1,965
  2,057
  2,148
  2,240
  2,333
  2,427
  2,524
  2,623
Issuance/(repurchase) of shares, $m
  232
  145
  166
  193
  228
  273
  329
  398
  480
  576
  684
  812
  956
  1,116
  1,292
  1,485
  1,694
  1,918
  2,157
  2,411
  2,680
  2,963
  3,260
  3,571
  3,895
  4,234
  4,586
  4,953
  5,334
  5,731
Cash from financing (excl. dividends), $m  
  202
  234
  291
  364
  454
  563
  694
  846
  1,018
  1,211
  1,422
  1,655
  1,907
  2,176
  2,460
  2,760
  3,074
  3,401
  3,741
  4,093
  4,458
  4,835
  5,225
  5,628
  6,043
  6,474
  6,919
  7,380
  7,858
  8,354
Total cash flow (excl. dividends), $m
  61
  87
  121
  163
  214
  274
  344
  421
  506
  596
  688
  786
  887
  988
  1,089
  1,189
  1,287
  1,383
  1,477
  1,569
  1,658
  1,746
  1,832
  1,918
  2,003
  2,089
  2,176
  2,264
  2,354
  2,446
Retained Cash Flow (-), $m
  -232
  -145
  -166
  -193
  -228
  -273
  -329
  -398
  -480
  -576
  -684
  -812
  -956
  -1,116
  -1,292
  -1,485
  -1,694
  -1,918
  -2,157
  -2,411
  -2,680
  -2,963
  -3,260
  -3,571
  -3,895
  -4,234
  -4,586
  -4,953
  -5,334
  -5,731
Prev. year cash balance distribution, $m
  4
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -168
  -58
  -45
  -30
  -14
  1
  14
  23
  26
  20
  4
  -25
  -69
  -128
  -203
  -296
  -407
  -535
  -680
  -843
  -1,022
  -1,217
  -1,427
  -1,653
  -1,892
  -2,145
  -2,411
  -2,690
  -2,981
  -3,284
Discount rate, %
  15.80
  16.59
  17.42
  18.29
  19.20
  20.17
  21.17
  22.23
  23.34
  24.51
  25.74
  27.02
  28.37
  29.79
  31.28
  32.85
  34.49
  36.21
  38.02
  39.93
  41.92
  44.02
  46.22
  48.53
  50.96
  53.50
  56.18
  58.99
  61.94
  65.03
PV of cash for distribution, $m
  -145
  -43
  -28
  -15
  -6
  0
  4
  5
  4
  2
  0
  -1
  -3
  -3
  -3
  -3
  -3
  -2
  -1
  -1
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  50.0
  5.6
  0.8
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

FINANCIAL RATIOS  of  Agenus (AGEN)

Valuation Ratios
P/E Ratio -1.5
Price to Sales 8.4
Price to Book -4.9
Price to Tangible Book
Price to Cash Flow -2.4
Price to Free Cash Flow -2.1
Growth Rates
Sales Growth Rate -8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 225%
Cap. Spend. - 3 Yr. Gr. Rate 67%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity -335.9%
Total Debt to Equity -335.9%
Interest Coverage -126
Management Effectiveness
Return On Assets -63.2%
Ret/ On Assets - 3 Yr. Avg. -64.2%
Return On Total Capital -91.7%
Ret/ On T. Cap. - 3 Yr. Avg. -140.3%
Return On Equity -793.8%
Return On Equity - 3 Yr. Avg. -474.4%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 66.7%
EBITDA Margin -526.1%
EBITDA Margin - 3 Yr. Avg. -481.1%
Operating Margin -465.2%
Oper. Margin - 3 Yr. Avg. -467.8%
Pre-Tax Margin -552.2%
Pre-Tax Margin - 3 Yr. Avg. -508.1%
Net Profit Margin -552.2%
Net Profit Margin - 3 Yr. Avg. -501.4%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 1.8%
Payout Ratio 0%

AGEN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AGEN stock intrinsic value calculation we used $42.877086 million for the last fiscal year's total revenue generated by Agenus. The default revenue input number comes from 0001 income statement of Agenus. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AGEN stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 15.8%, whose default value for AGEN is calculated based on our internal credit rating of Agenus, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Agenus.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AGEN stock the variable cost ratio is equal to 114%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $104 million in the base year in the intrinsic value calculation for AGEN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 12.8% for Agenus.

Corporate tax rate of 27% is the nominal tax rate for Agenus. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AGEN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AGEN are equal to 104.6%.

Life of production assets of 10.7 years is the average useful life of capital assets used in Agenus operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AGEN is equal to -52.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-75.815792 million for Agenus - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 86.882 million for Agenus is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Agenus at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
MRK Merck&Co 74.84 33.05  str.sell
GSK GlaxoSmithKlin 40.41 350.10  str.buy
INCY Incyte 65.03 161.51  str.buy
STML Stemline Thera 11.37 0.39  str.sell
VICL Vical 1.24 0.72  sell
CLDX Celldex Therap 0.340 0.12  str.sell

COMPANY NEWS

▶ Agenus: 3Q Earnings Snapshot   [07:54AM  Associated Press]
▶ Celyad (CYAD) Jumps: Stock Rises 6.8%   [Oct-05-18 08:48AM  Zacks]
▶ Agenus Receives Milestone Payment from Incyte   [Sep-17-18 09:00AM  PR Newswire]
▶ Why Agenus' Stock Perked Up in August   [Sep-07-18 07:32AM  Motley Fool]
▶ Agenus (AGEN) Continue to Surge Higher?   [Aug-31-18 04:30AM  Zacks]
▶ Is Agenus Inc. Stock a Buy?   [Aug-23-18 10:00AM  Motley Fool]
▶ Agenus Receives Second Milestone Payment from Merck   [Aug-15-18 01:22PM  PR Newswire]
▶ Agenus: 2Q Earnings Snapshot   [09:52AM  Associated Press]
▶ Agenus Inc. to Host Earnings Call   [06:30AM  ACCESSWIRE]
▶ Should Biotech Investors Fear Dilution?   [Jul-21-18 08:25AM  Motley Fool]
▶ Agenus Appoints Regulatory and Clinical Heads   [Jul-16-18 08:37AM  PR Newswire]
▶ Agenus to Webcast Annual Meeting of Stockholders   [Jun-20-18 08:00AM  PR Newswire]
▶ Is Agenus Inc. (AGEN) a Buy?   [May-12-18 09:28AM  Motley Fool]
▶ Agenus: 1Q Earnings Snapshot   [09:13AM  Associated Press]
▶ Agenus Inc. to Host Earnings Call   [08:15AM  ACCESSWIRE]
▶ 2 Beaten-Down Biotech Stocks That Look Like Bargains Now   [May-05-18 09:16AM  Motley Fool]
▶ Agenus reports 4Q loss   [08:45AM  Associated Press]
▶ Agenus Inc. to Host Earnings Call   [07:45AM  ACCESSWIRE]
▶ Steven Cohen Takes Stake in Biotech Company Agenus   [Mar-07-18 10:19AM  GuruFocus.com]
▶ Why Agenus Stock Spiked Tuesday   [Feb-21-18 08:48AM  Motley Fool]
▶ Is Agenus Inc. a Buy?   [Feb-13-18 07:31AM  Motley Fool]
▶ 3 Biotech Stocks Start Healthy in 18: Will the Rally Last?   [Jan-18-18 01:55PM  InvestorPlace]
▶ Will 2018 Be Agenus Inc.'s Best Year Yet?   [10:00AM  Motley Fool]
▶ Agenus Inc., (AGEN) Jumps: Stock Rises 11.4%   [Jan-09-18 08:48AM  Zacks]
▶ Why Agenus Inc. Stock Sank in December   [Jan-06-18 08:00AM  Motley Fool]
▶ ETFs with exposure to Agenus, Inc. : January 2, 2018   [Jan-02-18 11:01AM  Capital Cube]
▶ ETFs with exposure to Agenus, Inc. : December 22, 2017   [Dec-22-17 11:30AM  Capital Cube]
▶ ETFs with exposure to Agenus, Inc. : December 11, 2017   [Dec-11-17 01:22PM  Capital Cube]
▶ Agenus Inc (AGEN)s Earnings Grew 12.7%, Is It Enough?   [Dec-01-17 06:50PM  Simply Wall St.]
▶ ETFs with exposure to Agenus, Inc. : November 30, 2017   [Nov-30-17 01:12PM  Capital Cube]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.